title: Changes in plasma thiol levels induced by different phases of treatment in breast cancer; the role of commercial extract from black chokeberry.
abstract: Different low-molecular-weight thiols, including glutathione, cysteine, and cysteinylglycine are physiological free radical scavengers. On the other hand, homocysteine may play a role as an oxidant. The aim of our present study was to establish in vitro the effects of the commercial extract of Aronia melanocarpa (Aronox(®)) on the amount of selected low-molecular-weight thiols and the activity of antioxidative enzymes (superoxide dismutase, glutathione peroxidase, and glutathione reductase) in plasma obtained from patients with invasive breast cancer during different phases of treatment [before or after the surgery and patients after different phases of chemotherapy (doxorubicin and cyclophosphamide)] and from healthy subjects. Patients were hospitalized in Department of Oncological Surgery and Department of Chemotherapy, Medical University of Lodz, Poland. The level of low-molecular-weight thiols was determined by high-performance liquid chromatography. We observed that in the presence of the Aronia extract changes in amount of thiols in plasma from breast cancer patients (at all tested groups) were significantly reduced. Our results showed that tested commercial extract reduced modifications of antioxidative enzymes activity in plasma from patients during different phases of treatment, but this effect was not statistical significant. Our results suggest that the Aronia extract supplementation in breast cancer patients has a beneficial effect on thiols concentration in plasma. Plasma, as reported in this work, could be used as an experimental model to evaluate the beneficial action of plant supplements, including phenolic extracts on thiols or other molecules during different phases of treatment.
authors.affiliation: The Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/3, 90-236 Lodz, Poland.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Kędzierska
authors.forename: Rafał
authors.initials: R
authors.lastname: Głowacki
authors.forename: Urszula
authors.initials: U
authors.lastname: Czernek
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Szydłowska-Pazera
authors.forename: Piotr
authors.initials: P
authors.lastname: Potemski
authors.forename: Janusz
authors.initials: J
authors.lastname: Piekarski
authors.forename: Arkadiusz
authors.initials: A
authors.lastname: Jeziorski
authors.forename: Beata
authors.initials: B
authors.lastname: Olas
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000097:blood* / Q000201:enzymology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000097:blood* / Q000201:enzymology / Q000628:therapy; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003545:Cysteine / Q000097:blood*; D004151:Dipeptides / Q000097:blood*; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005978:Glutathione / Q000097:blood*; D005979:Glutathione Peroxidase / Q000097:blood; D005980:Glutathione Reductase / Q000097:blood; D006801:Humans; D008875:Middle Aged; D046936:Photinia; D010936:Plant Extracts / Q000008:administration & dosage*; D013482:Superoxide Dismutase / Q000097:blood
chemical_list: D000903:Antibiotics, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D000975:Antioxidants; D004151:Dipeptides; D010936:Plant Extracts; C028505:cysteinylglycine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005980:Glutathione Reductase; D005978:Glutathione; D003545:Cysteine